Date | Time | Source | Announcement |
---|---|---|---|
07 Feb 2006 | 07:00 AM | Re: Manufacturing Contract | |
06 Feb 2006 | 07:01 AM | Research Update | |
24 Jan 2006 | 07:00 AM | Re US Patent Office | |
06 Dec 2005 | 10:03 AM | Re Conference | |
02 Dec 2005 | 11:19 AM | Re: Government Support | |
30 Nov 2005 | 07:00 AM | Interim Results | |
23 Nov 2005 | 04:57 PM | Notice of Results | |
18 Nov 2005 | 07:00 AM | Research Update | |
25 Oct 2005 | 07:00 AM | Research Update | |
05 Oct 2005 | 09:59 AM | Holding(s) in Company | |
22 Sep 2005 | 10:31 AM | Research Update | |
20 Sep 2005 | 09:13 AM | Director/PDMR Shareholding | |
16 Sep 2005 | 01:08 PM | Director/PDMR Shareholding | |
16 Sep 2005 | 01:06 PM | Director/PDMR Shareholding | |
16 Sep 2005 | 01:05 PM | Director/PDMR Shareholding | |
16 Sep 2005 | 01:03 PM | Director/PDMR Shareholding | |
16 Sep 2005 | 01:01 PM | Director/PDMR Shareholding | |
12 Aug 2005 | 07:00 AM | Admission to Trading on AIM |
ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
It listed on AIM in 2006 under the ticker RENE.